Iovance Biotherapeutics Inc (IOVA) is a biotechnology company that develops and commercializes cancer immunotherapy products to treat various types of cancer. The company's products are based on Tumor Infiltrating Lymphocyte (TIL) technology, which involves removing TILs from a patient's tumor, expanding them in the laboratory, and then infusing them back into the patient's body to fight cancer.
IOVA's lead product candidate, lifileucel, is being developed for the treatment of metastatic melanoma and advanced cervical cancer. The company is also developing LN-145 for the treatment of cervical and head and neck cancers.
IOVA is headquartered in San Carlos, California, and was founded in 2007.
Iovance Biotherapeutics Inc (IOVA) is a biotechnology company that develops and commercializes cancer immunotherapy products to treat various types of cancer. The company's products are based on Tumor Infiltrating Lymphocyte (TIL) technology, which involves removing TILs from a patient's tumor, expanding them in the laboratory, and then infusing them back into the patient's body to fight cancer.